Related Experiment Video
Updated: Jun 10, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry
Jennifer Rymer1, Cayla Pichan2, Courtney Page3
1Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Insights
Cangrelor infusion was longer in patients with myocardial infarction and cardiogenic shock. Longer infusions were linked to increased bleeding risk, highlighting the need for further research into antiplatelet pharmacodynamics in this patient group.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Limited understanding exists regarding cangrelor use in patients experiencing myocardial infarction (MI) complicated by cardiogenic shock (CS).
- This study addresses the knowledge gap concerning cangrelor's effectiveness and safety profile in this high-risk patient population.
Purpose of the Study:
- To evaluate the duration of cangrelor infusion and the transition time to oral P2Y12 inhibitors in patients with MI and CS.
- To assess the risks of major adverse cardiovascular events (MACEs) and bleeding associated with different cangrelor infusion strategies and transition times.
- To identify factors influencing cangrelor infusion duration in patients with CS.
Main Methods:
- The CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) registry, a multicenter observational study, was utilized.
- Data from 249 patients with MI and CS treated with cangrelor were analyzed.
- Infusion durations, transition times to oral P2Y12 inhibitors, MACEs, and bleeding events were assessed, stratified by dosage and transition parameters.
Main Results:
- Patients with CS received longer cangrelor infusions (median 3.9 hours) compared to the overall MI cohort (median 2 hours).
- Mechanical circulatory support (MCS) use and chronic lung disease were associated with longer cangrelor infusions (>3.9 hours).
- In patients with CS, 24.1% experienced bleeding events, and 41.8% had MACEs; longer infusion duration correlated with increased bleeding risk.
Conclusions:
- Cangrelor infusion durations are extended in patients with MI and CS, particularly those requiring MCS.
- A longer cangrelor infusion duration is associated with a higher risk of bleeding in this population.
- Further investigation is warranted to elucidate the pharmacodynamics of antiplatelet agents in patients with CS.
Introduction:
Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS).
Methods:
CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluating platelet inhibition in patients with MI. We examined the duration of cangrelor infusion and the amount of time to transition from cangrelor to an oral P2Y12 inhibitor in patients with CS. We also assessed major adverse cardiovascular events (MACEs) and bleeding risks, stratified by dosage duration, time to transition and oral P2Y12 inhibitor potency.
Results:
Among 2352 cangrelor-treated patients with MI, 249 patients were in CS. Among the patients with CS, 16 (6.4%) received the "bridge" infusion dose, 202 (81.1%) the PCI cangrelor infusion dose, and 30 (12.0%) had a combination of both infusion doses. Patients with CS had a median age of 66 years; 32% were women; 21% were Black patients; 35% had diabetes; 19% received thrombectomy; and 59% received mechanical circulatory support (MCS) (35% intra-aortic balloon pump, 27% Impella). The median duration of infusion was 3.9 (2-21.5 hours) in patients with CS and was 2 (1.6-3.1 hours) for all cangrelor-treated patients. The median duration of transition from cangrelor to oral P2Y12 inhibitor administration was 0.1 (-0.5-21.0 hours) for patients with CS. In multivariable modeling, chronic lung disease and the use of MCS and was associated with longer cangrelor infusions (defined as > 3.9 hours). Among cangrelor-treated patients with CS, 24.1% of these patients had a bleeding event, and 41.8% had a MACE event. After adjustment, a longer cangrelor infusion duration was associated with increased risk of bleeding (P < 0.05).
Conclusions:
The median duration of cangrelor infusion was longer for patients presenting with CS. Use of MCS was associated with longer cangrelor infusion durations in patients with CS. Further work is needed to understand the pharmacodynamics of antiplatelet agents in patients with CS.
More Related Videos
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Acute Coronary SyndromeI: Introduction
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:26Coronary Artery Disease IV: Medical Management
01:19Acute Coronary Syndrome II: Pathophysiology and clinical manifestations
01:30Acute Coronary Syndrome III: Diagnostic studies